Chemically Engineered L. reuteri Delivering αPD‐L1 and Gallium Ions via Metal‐Phenolic Networks Potentiate Anti‐Tumor Immunity and Ferroptosis
Source abstract
Abstract
ABSTRACT Bacterial‐based materials, leveraging their inherent hypoxia and immunosuppressive microenvironment‐targeting capabilities, immunomodulatory effects, and drug delivery advantages, have emerged as promising strategies to modulate the tumor microenvironment (TME) for converting immunologically “cold” tumors into “hot” ones. This study innovatively functionalizes Lactobacillus reuteri ( L. reuteri ) using metal‐phenolic networks (MPNs) to co‐deliver αPD‐L1 antibodies and gallium ions (Ga 3 + ) for synergistic anti‐tumor therapy. The MPN coating materials enable pH‐responsive drug release, whereby αPD‐L1 reverses immunosuppression and Ga 3 + disrupts tumor iron metabolism, mimicking Fe 3 + to induce selective ferroptosis. In vivo evaluations in B16 and LLC tumor‐bearing mouse models revealed that functionalized L. reuteri had the potential to reprogram the tumor immune microenvironment and significantly enhanced tumor regression. This system achieved multifunctional tumor regression in vivo, integrating bacterial hypoxia‐driven chemotaxis, MPN‐mediated ferroptosis, and immune checkpoint inhibitors (ICIs)‐driven immune activation. Thus, the multifunctional materials offer a novel strategy for treating refractory or immunologically “cold” tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Ferroptosis and cancer prognosis · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
Institute of Health and Medicine Hefei Comprehensive National Science Center Hefei Anhui China
Funding
National Natural Science Foundation of China
References (27)
Show source-provided references
1. 10.1021/acsnano.8b0223510.1021/acsnano.8b02235 ↗
2. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
3. 10.1016/j.tibs.2015.12.00110.1016/j.tibs.2015.12.001 ↗
4. 10.1016/j.addr.2022.11444310.1016/j.addr.2022.114443 ↗
5. 10.1111/jam.1429710.1111/jam.14297 ↗
6. 10.1016/j.canlet.2019.01.03710.1016/j.canlet.2019.01.037 ↗
7. 10.1080/19490976.2023.218611410.1080/19490976.2023.2186114 ↗
8. 10.1158/2326‐6066.Cir‐20‐005110.1158/2326‐6066.Cir‐20‐0051 ↗
9. 10.1186/s13045‐025‐01690‐610.1186/s13045‐025‐01690‐6 ↗
10. 10.1016/j.biopha.2025.11801410.1016/j.biopha.2025.118014 ↗
11. 10.1200/jco.21.0184510.1200/jco.21.01845 ↗
12. 10.1186/s12964‐022‐00854‐y10.1186/s12964‐022‐00854‐y ↗
13. 10.1016/j.cell.2023.03.01110.1016/j.cell.2023.03.011 ↗
14. 10.1016/j.bsheal.2025.09.00210.1016/j.bsheal.2025.09.002 ↗
15. 10.1016/j.ijpharm.2023.12322910.1016/j.ijpharm.2023.123229 ↗
16. 10.1002/advs.20230726910.1002/advs.202307269 ↗
17. 10.1002/smll.20210391910.1002/smll.202103919 ↗
18. 10.1016/j.bioactmat.2024.02.03610.1016/j.bioactmat.2024.02.036 ↗
19. 10.1016/j.ijpharm.2019.03.00910.1016/j.ijpharm.2019.03.009 ↗
20. 10.1002/adma.20250125610.1002/adma.202501256 ↗
21. 10.1002/anie.20230783810.1002/anie.202307838 ↗
22. 10.1016/j.phrs.2016.11.00910.1016/j.phrs.2016.11.009 ↗
23. 10.1016/j.ccell.2022.02.00310.1016/j.ccell.2022.02.003 ↗
24. 10.1016/j.bsheal.2025.01.00410.1016/j.bsheal.2025.01.004 ↗
25. 10.1002/smll.20230270210.1002/smll.202302702 ↗
26. 10.1016/j.bsheal.2025.05.00310.1016/j.bsheal.2025.05.003 ↗
27. 10.1002/wnan.186410.1002/wnan.1864 ↗